InvestSMART

BlinkLab Limited (ASX:BB1)

ALERT: Price-sensitive ASX Announcement for BB1
Current share price for BB1 : $0.690 0.015 (2.22%)+
Announcement
Release
5 Aug 2026 9:15AM
Price at Release
$0.675
Full Release
download
Summary
BlinkLab Limited, trading as BB1 on the ASX, announced positive results from their European study on ADHD, highlighting the effectiveness of their smartphone-based digital neurobehavioural biomarkers for diagnosing ADHD in children. The study, conducted in collaboration with the Mental Care Group (MCG) in Europe, achieved sensitivity and specificity of 82% and 83%, respectively. This marks a significant step towards the development of BlinkLab Dx2, a diagnostic tool for ADHD and autism. The study's results, which are some of the largest case-control datasets for ADHD assessment, suggest the potential for reducing subjective diagnostic processes and improving clinical workflows. BlinkLab plans to follow a similar regulatory pathway in the US as it did for its autism product, planning a pilot study in the US followed by FDA registration. The company aims to expand its diagnostic platform's capabilities beyond paediatric autism to address a significant unmet medical need in ADHD diagnosis.
Key Points
  • BlinkLab Limited reports successful European ADHD study results.
  • Study achieved 82% sensitivity and 83% specificity.
  • Potential expansion of BlinkLab Dx2 model to include ADHD.
  • Collaboration with Mental Care Group in Europe was cost-effective.
  • Study represents one of the largest ADHD case-control datasets.
  • BlinkLab plans to initiate a U.S. pilot study followed by FDA registration.
  • Smartphone-based assessments used digital neurobehavioural biomarkers.
  • Technology aims to complement clinical judgment and improve ADHD diagnostics.
  • Development strategy follows successful path of BlinkLab Dx1 for autism.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.